Marker Therapeutics Inc (MRKR)

[Sugarshaker]

New updated milestones for 2017,

2Q 2017: On track to achieve 50% enrollment in ongoing Phase 2 dosing study of TPIV 200 for treating triple-negative breast cancer (TNBC)
3Q 2017: Publish long-term safety, immune response and survival data from completed Phase 1 clinical study of TPIV 200
3Q 2017: Report interim results from ongoing Phase 2 study of TPIV 200 in combination with AstraZeneca's durvalumab in patients with platinum-resistant ovarian cancer
3Q 2017: Mayo Clinic to initiate 280-patient Phase 2 study of TPIV 200 in women
with advanced triple-negative breast cancer
3Q 2017: On track to complete enrollment in Phase 2 dosing study of TPIV 200 in TNBC
4Q 2017: TPIV 100/110 File amended IND; initate phase 1b/2 HER2/neu + breast cancer study
4Q 2017/1Q 2018- TPIV100/110 Mayo Clinic to initate Phase 1b/2 HER2/nue + DCIS study
Year end 2017: File amended investigational new drug application (IND) for TPIV 110 for treating HER2/neu+ breast cancer.

Wow really hope Glynn can achieve all this,if so hang on boys and girls.